BC Week In Review | Sep 26, 2011
Clinical News

Compugen preclinical data

Compugen announced in vitro validation of CGEN-15091, its third drug candidate based on the B7/ CD28 co-stimulatory protein family with therapeutic potential in autoimmune diseases and cancer. CGEN-15091, along with Compugen's CGEN-15021 and CGEN-15001 , are...
Items per page:
1 - 1 of 1